Mechanisms of disease - The biology of chronic myeloid leukemia

被引：967

作者：

Faderl, S

Talpaz, M

Estrov, Z

O'Brien, S

Kurzrock, R

Kantarjian, HM

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1999年 / 341卷 / 03期

关键词：

D O I：

10.1056/NEJM199907153410306

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：164 / 172

页数：9

共 75 条

[1] DIFFERENTIAL COMPLEMENTATION OF BCR-ABL POINT MUTANTS WITH C-MYC [J].

AFAR, DEH ;

GOGA, A ;

MCLAUGHLIN, J ;

WITTE, ON ;

SAWYERS, CL .

SCIENCE, 1994, 264 (5157) :424-426

[2] ALTERATIONS IN THE P53 GENE AND THE CLONAL EVOLUTION OF THE BLAST CRISIS OF CHRONIC MYELOCYTIC-LEUKEMIA [J].

AHUJA, H ;

BARELI, M ;

ADVANI, SH ;

BENCHIMOL, S ;

CLINE, MJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6783-6787

[3] Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia [J].

Bhatia, R ;

McCarthy, JB ;

Verfaillie, CM .

BLOOD, 1996, 87 (09) :3883-3891

[4]

BIERNAUX C, 1995, BLOOD, V86, P3118

[5] The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].

Bose, S ;

Deininger, M ;

Gora-Tybor, J ;

Goldman, JM ;

Melo, JV .

BLOOD, 1998, 92 (09) :3362-3367

[6]

BROWN RD, 1986, BLOOD, V68, P37

[7] A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia [J].

Buño, I ;

Wyatt, WA ;

Zinsmeister, AR ;

Dietz-Band, J ;

Silver, RT ;

Dewald, GW .

BLOOD, 1998, 92 (07) :2315-2321

[8] The ABL genes in normal and abnormal cell development [J].

Chung, SW ;

Daniel, R ;

Wong, BY ;

Wong, PMC .

CRITICAL REVIEWS IN ONCOGENESIS, 1996, 7 (1-2) :33-48

[9] CYTOKINETIC CONSIDERATIONS RELEVANT TO DEVELOPMENT OF A SUCCESSFUL THERAPEUTIC STRATEGY IN CHRONIC MYELOGENOUS LEUKEMIA (CML) [J].

CLARKSON, B ;

STRIFE, A .

LEUKEMIA & LYMPHOMA, 1993, 11 :101-107

[10] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].

Collins, RH ;

Shpilberg, O ;

Drobyski, WR ;

Porter, DL ;

Giralt, S ;

Champlin, R ;

Goodman, SA ;

Wolff, SN ;

Hu, W ;

Verfaillie, C ;

List, A ;

Dalton, W ;

Ognoskie, N ;

Chetrit, A ;

Antin, JH ;

Nemunaitis, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444

← 1 2 3 4 5 6 7 8 →